Fig. 5: Schematic diagram of AKI modeling and treatment process, and therapeutic assessments of MF-0 via intravenous injection for AKI. | Nature Communications

Fig. 5: Schematic diagram of AKI modeling and treatment process, and therapeutic assessments of MF-0 via intravenous injection for AKI.

From: Valence-engineered catalysis-selectivity regulation of molybdenum oxide nanozyme for acute kidney injury therapy and post-cure assessment

Fig. 5: Schematic diagram of AKI modeling and treatment process, and therapeutic assessments of MF-0 via intravenous injection for AKI.

a Timeline of AKI modeling and treatment with mice. CRE (b) and BUN (c) levels in the blood serum from each group after indicated treatments (n = 3; Data are presented as means ± SD. *P < 0.1, n.s. no significance. P values in (b): 2.0 × 10–2, 2.1 × 10–2, 1.8 × 10–1 and 2.3 × 10–2, P values in (c): 3.4 × 10–2, 2.9 × 10–2, 2.6 × 10–1 and 5.6 × 10–2). d The survival rate of AKI mice treated with PBS and MF-0, respectively. e H&E staining of renal sections from each treatment group. Arrows indicated damaged tubules and asterisks indicated the formation of casts (a marker of more severe tubular damage). f DAPI (blue fluorescence indicating cell nuclei) and dihydroethidium (red fluorescence indicating ROS level) staining of kidney tissues from each treatment group. NAC used in (b, c, e, f) was a ROS inhibitor. The injection dosage of agents in different treatment groups was 200 μL: NAC (800 μg/mL), MF-0 (800 μg of Mo per mL). Significance was calculated by one-sided Student’s t-test. Source data are provided as a Source Data file.

Back to article page